Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01274273|
Recruitment Status : Unknown
Verified August 2012 by University of Aarhus.
Recruitment status was: Active, not recruiting
First Posted : January 11, 2011
Last Update Posted : December 2, 2014
|Condition or disease||Intervention/treatment||Phase|
|Metastatic Renal Cell Carcinoma||Drug: Interleukin-2 Drug: Interferon Alfa-2b Drug: Bevacizumab||Phase 2|
Bevacizumab as monotherapy has effect in metastatic renal cell carcinoma (mRCC). Bevacizumab in combination with interferon-alfa (IFN-α) has significant efficacy in mRCC and has been approved by EMA and FDA.
The present study will assess whether the combination of Interleukin-2 (IL-2) and IFN-α with bevacizumab may add efficacy in patients with mRCC with a tolerable safety profile.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||118 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Randomized Phase II Trial of IL-2/IFN-α Plus Bevacizumab Versus IL-2/IFN-α in Metastatic Renal Cell Carcinoma (mRCC) - Danish Renal Cancer Group (DARENCA) Study-1|
|Study Start Date :||October 2009|
|Estimated Primary Completion Date :||December 2015|
|Estimated Study Completion Date :||December 2015|
|Experimental: Interleukin-2, interferon, bevacizumab||
Bevacizumab doses of 10 mg per kilogram of body weight, given every two weeks i.v. until disease progression, unacceptable toxicity, withdrawal of consent or a maximum of 1 year following obtaining no evidence of disease (NED).
Other Name: Avastin
|Active Comparator: Interleukin-2 and interferon-alfa||
2.4 MIU/m2 s.c. two times daily, 5 days per week, weeks 1 and 2, every 28-day-cycle, for a maximum of 9 cycles (i.e.for a maximum of 9 months).
Other Name: Aldesleukin
Drug: Interferon Alfa-2b
IFN-alfa given as one priming-week of daily IFN 3.0 MIU, followed by up to 9 treatment cycles (i.e. for a maximum of 9 months) with IFN-alfa 3.0 MIU as a fixed dose s.c. once daily - 5 days per week.
Other Name: IntronA
- Progression free survival, PFS [ Time Frame: This is defined as the time between date of randomisation and the first date of documented disease progression or date of death due to any cause. ]
- Response rate, RR [ Time Frame: Overall response rate as assessed by the RECIST 1.1 criteria. An overall response is defined as a confirmed complete response (CR) or confirmed partial response (PR). ]
- Overall survival, (OS) [ Time Frame: Overall survival is defined as the time between date of randomisation and the date of death due to any cause. ]
- Duration of response [ Time Frame: Duration of response is defined as the time between the date a response (CR or PR) was first seen until date of progression. ]
- Time to progression, (TTP) [ Time Frame: Time to progression is defined as time between date of randomisation and date of documented progression. ]
- Time to treatment failure, (TTTF) [ Time Frame: see below ]Time to treatment failure is defined as time between date of randomisation and date of insufficient therapeutic response (including disease progression), death, withdrawal of treatment due to adverse events or laboratory abnormality, or withdrawn informed consent.
- Tolerability [ Time Frame: see below ]Toxicity is recorded according to CTCAE v3.0
- Frequency of surgical resection of residual disease [ Time Frame: see below ]This is calculated as number of patients having surgical resection of residual disease compared with the total number of treated patients.
- Frequency of no evidence of disease (NED) [ Time Frame: see below ]This is calculated as the total number of patients having no evidence of disease as a result of CR to treatment, or as a result of PR/SD to treatment followed by surgical resection of residual disease, compared with the total number of treated patients.
- To explore the immunomodulatory effect of therapy in serial blood samples and serial tumor core biopsies and to correlate these biomarkers with outcome [ Time Frame: see below ]
Blood tests and core biopsies from accessible tumor lesions will be obtained at baseline, after cycle 1 and at PD.
Blood analyses will include assessment of dendritic cells, FoxP3+ regulatory T-cells, NK-cells, T-subsets, neutrophils, monocytes, cytotoxic activity and antibody-dependent cellular cytotoxicity (ADCC).
Tumor analyses will include assessment of intratumoral immune cells, markers related to HIF accumulation and CD34+ microvessel density.
- To assess dynamic contrast-enhanced imaging as a potential biomarker. [ Time Frame: see below ]
Dynamic contrast-enhanced imaging (CT, MRI, and US) will be obtained at baseline, week 5 and at routine tumor assessments, if appropriate, for estimation of tumor blood perfusion change.
An exploratory analysis to identify any potential relationship between each of these assessments and outcome (progression free survival, survival, time to progression, response rate and safety) will be performed.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01274273
|Aarhus University Hospital|
|Aarhus, Denmark, 8000|
|Herlev University Hospital|
|Herlev, Denmark, 2730|
|Principal Investigator:||Frede Donskov, MD, DMSc||Aarhus University Hospital|
|Study Chair:||Poul Geertsen, MD, PhD||University of Copenhagen|